AGTC expands gene therapy manufacturing capabilities
Applied Genetic Technologies (AGTC) has initiated plans to lease a build-to-suit 21,000-sq-ft current good manufacturing practice manufacturing and quality control facility in Florida. Read More
EBRC explains new ethics in engineering research statement
The Engineering Biology Research Consortium (EBRC) has published a companion paper to its Statement of Ethics in Engineering Biology Research. The new viewpoint paper was published in ACS Synthetic Biology on May 12. Read More
NanoCellect launches new cell sorter
NanoCellect Biomedical announced it has scheduled a virtual launch for its Wolf G2 Cell Sorter. Read More
PerkinElmer to acquire Nexcelom for $260M
PerkinElmer has entered into an agreement to acquire life sciences instrumentation firm Nexcelom Bioscience for $260 million, a deal that is expected to be completed in the second quarter of 2021. Read More
Potential of gene editing for clinical use highlighted at ASGCT 2021
From base editing to in vivo CRISPR therapeutics and CRISPR-modified bacteriophages, scientists discussed innovations in preclinical research that have allowed them to advance these unique products to the clinic during a scientific symposium at the 2021 American Society of Gene & Cell Therapy (ASGCT) virtual meeting. Read More
Nobel Prize winner Doudna shares perspectives on future of CRISPR gene editing
Small science can translate into big discoveries, according to Nobel Prize laureate Jennifer Doudna, PhD. She discussed how her curiosity in understanding CRISPR led to the gene editing revolution in a talk at the 2021 American Society of Gene & Cell Therapy virtual meeting. Read More
Nuclera acquires E Ink unit, creates bioprinter
Nuclera has acquired E Ink's microfluidics unit, and, together, they have developed a desktop bioprinter that will be commercially available in 2022. Read More
Cellectis, Sanofi partner on UCART clinical trials
Sanofi has agreed to supply anti-CD52 monoclonal antibody alemtuzumab for use in a lymphodepleting regimen in Cellectis-sponsored universal chimeric antigen receptor T-cell (UCART) trials. Read More
ERS Genomics, GenScript sign CRISPR/Cas9 license deal
ESR Genomics has agreed to nonexclusively license its CRISPR/Cas9 patent portfolio to GenScript. Read More
Lilly, MiNA collaborate on saRNA research
Eli Lilly is teaming up with RNA activation therapeutics firm MiNA Therapeutics on a global research collaboration to develop drug candidates using MiNA's small activating RNA (saRNA) technology platform. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter